SMURF2
E3 ubiquitin-protein ligase SMURF2
Protein Summary
E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Interacts with SMAD1 and SMAD7 in order to trigger their ubiquitination and proteasome-dependent degradation. In addition, interaction with SMAD7 activates autocatalytic degradation, which is prevented by interaction with SCYE1. Forms a stable complex with the TGF-beta receptor-mediated phosphorylated SMAD2 and SMAD3. In this way, SMAD2 may recruit substrates, such as SNON, for ubiquitin-mediated degradation. Enhances the inhibitory activity of SMAD7 and reduces the transcriptional activity of SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable decrease in steady-state level of SMAD1 protein and a smaller decrease of SMAD2 level.
- ENST00000262435
- ENSP00000262435
- ENSG00000108854
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
hub protein | 0.92 | ||
biological process | 0.89 | ||
interacting protein | 0.84 | ||
kinase perturbation | 0.81 | ||
virus perturbation | 0.68 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 135.99 (req: < 5)
Gene RIFs: 86 (req: <= 3)
Antibodies: 291 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 135.99 (req: >= 5)
Gene RIFs: 86 (req: > 3)
Antibodies: 291 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 21
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 5
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0